Journal
GENE THERAPY
Volume 20, Issue 1, Pages 7-15Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/gt.2011.205
Keywords
oncolytic; measles; melanoma; immunotherapy; HMGB1; interferon
Categories
Funding
- Medical Research Council (UK)
- Cancer Research UK
- MRC [G0900324] Funding Source: UKRI
- Cancer Research UK [13244] Funding Source: researchfish
- Medical Research Council [G0900324] Funding Source: researchfish
- National Institute for Health Research [ACF-2006-02-006] Funding Source: researchfish
Ask authors/readers for more resources
Oncolytic viruses (OV) are promising treatments for cancer, with several currently undergoing testing in randomised clinical trials. Measles virus (MV) has not yet been tested in models of human melanoma. This study demonstrates the efficacy of MV against human melanoma. It is increasingly recognised that an essential component of therapy with OV is the recruitment of host antitumour immune responses, both innate and adaptive. MV-mediated melanoma cell death is an inflammatory process, causing the release of inflammatory cytokines including type-1 interferons and the potent danger signal HMGB1. Here, using human in vitro models, we demonstrate that MV enhances innate antitumour activity, and that MV-mediated melanoma cell death is capable of stimulating a melanoma-specific adaptive immune response. Gene Therapy (2013) 20, 7-15; doi:10.1038/gt.2011.205; published online 15 December 2011
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available